Trial Profile
A Phase II, Open Label Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Ixabepilone (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 29 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Sep 2009 Actual patient number (54) added as reported by ClinicalTrials.gov.
- 12 May 2009 Planned number of patients changed from 54 to 57 as reported by ClinicalTrials.gov.